Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Ann Surg Oncol. 2019 Nov 11;27(5):1679–1692. doi: 10.1245/s10434-019-08050-y

Table 2.

Predictors of Delay to Surgery

Odds Ratio Estimates
Estimate 95% Confidence Limits P-value
Phenotype HER2+ REF
TN 0.82 0.79 0.84 <0.001
HR+ 1.01 0.98 1.03 0.625
Age <50 REF
50–59 0.98 0.96 1.00 0.047
60–69 0.96 0.94 0.98 0.001
≥ 70 0.84 0.81 0.86 <0.001
Race White REF
Black 1.71 1.67 1.76 <0.001
Asian 1.03 0.99 1.07 0.183
Other/Unknown 1.11 1.05 1.17 0.002
Hispanic No REF
Yes 1.3 1.26 1.35 <0.001
Unknown 0.97 0.93 1.02 0.192
Insurance Private Insurance REF
Medicaid 1.76 1.71 1.82 <0.001
Medicare 1.12 1.09 1.14 <0.001
Other Government 1.34 1.25 1.43 <0.001
Not Insured 1.44 1.36 1.52 <0.001
Unknown 1.13 1.05 1.21 0.001
Education ≥ 21% REF
13% - 20.9% 0.96 0.93 0.98 0.002
7%−12.9% 0.92 0.89 0.95 <0.001
< 7% 0.86 0.83 0.89 <0.001
Income < $38,000 REF
$38,000 - $47,999 0.97 0.95 1.00 0.023
$48,000 - $62,999 0.97 0.94 0.99 0.015
$63,000 + 0.90 0.87 0.94 <0.001
Setting Large metropolitan REF
Small metropolitan 0.95 0.92 0.98 0.001
Suburban 0.91 0.87 0.94 <0.001
Rural 0.86 0.81 0.90 <0.001
Unknown 0.99 0.94 1.04 0.670
Facility Volume 1st quartile: 0–45 pts/year 0.73 0.64 0.82 <0.001
2nd quartile: 46–82 pts/year 0.78 0.70 0.88 <0.001
3rd quartile: 83–152 pts/year 0.83 0.74 0.93 0.002
4th quartile: >152 pts/year REF
Distance (miles) ≤ 10 REF
11–20 0.99 0.97 1.01 0.148
21–40 0.98 0.95 01.0 0.035
>40 1.04 1.00 1.07 0.044
Unknown 1.31 0.67 2.54 0.428
Transition No REF
Yes 1.58 1.55 1.61 <0.001
Unknown 0.97 0.95 0.99 0.003
Year of Diagnosis 2010 0.72 0.70 0.74 <0.001
2011 0.76 0.75 0.78 <0.001
2012 0.83 0.81 0.85 <0.001
2013 0.92 0.90 0.93 <0.001
2014 REF
Comorbidities 0 0.70 0.64 0.76 <.0001
1 0.79 0.72 0.85 <0.001
2 0.90 0.83 0.99 0.033
≥3 REF
Histology Ductal REF
Lobular 1.10 1.07 1.12 <0.001
Other 1.00 0.95 1.05 0.914
Grade Well REF
Moderate 0.98 0.96 1.00 0.014
Poor 0.86 0.84 0.88 <0.001
Undifferentiated/Anaplastic 0.91 0.77 1.08 0.273
Unknown 0.99 0.95 1.02 0.522
Tumor Size <10mm REF
10–19mm 0.98 0.96 0.99 0.008
≥ 20mm 0.93 0.91 0.96 <0.001
Unknown 1.05 0.98 1.11 0.157
Stage I 0.91 0.87 0.94 <0.001
II 0.94 0.91 0.97 <0.001
III REF
Surgery Type Breast Conservation REF
Mastectomy 1.36 1.32 1.39 <0.001
Mastectomy with Reconstruction 2.99 2.92 3.07 <0.001
Chemotherapy No REF
Yes 0.79 0.78 0.81 <0.001
Radiation No REF
Yes 0.83 0.82 0.85 <0.001
Endocrine therapy No REF
Yes 0.87 0.86 0.89 <0.001
Nodes examined 0–1 REF
2 1.02 1.00 1.04 0.143
3–4 1.00 0.98 1.03 0.672
≥5 0.96 0.94 0.98 0.002
Positive Nodes 0 REF
≥1 1.13 1.1 1.16 <0.001
No nodes examined 1.31 1.26 1.37 <0.001

TN = Triple negative, HR+ = Hormone Receptor-Positive, HER2+ = HER2−enriched, REF=Referent